PRESS RELEASE published on 05/15/2025 at 07:00, 10 months 11 days ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 11 months 16 days ago Relief Therapeutics annonce ses résultats financiers et ses progrès stratégiques pour 2024 Biopharmaceutique Maladies Rares THÉRAPEUTIQUE DE SECOURS Résultats Financiers 2024 Progrès Du Pipeline
BRIEF published on 04/10/2025 at 07:05, 11 months 16 days ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
PRESS RELEASE published on 04/10/2025 at 07:00, 11 months 16 days ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year ago Relief Therapeutics met fin aux discussions de fusion avec Renexxion Valeur Actionnariale Objectifs Stratégiques THÉRAPEUTIQUE DE SECOURS Renexxion Fin De La Fusion
BRIEF published on 03/06/2025 at 07:05, 1 year ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
PRESS RELEASE published on 03/06/2025 at 07:00, 1 year ago Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics terminates merger discussions with Renexxion after failing to meet key conditions. Company remains well-positioned with robust pipeline and cash reserves Relief Therapeutics Cash Reserves Therapeutic Pipeline Renexxion Merger Discussions
BRIEF published on 02/11/2025 at 07:05, 1 year 1 month ago L'Office européen des brevets accorde un brevet thérapeutique de secours pour le RLF-TD011 Produits Biopharmaceutiques THÉRAPEUTIQUE DE SECOURS RLF-TD011 Brevet Européen Epidermolyse Bulleuse
BRIEF published on 02/11/2025 at 07:05, 1 year 1 month ago European Patent Office Grants Relief Therapeutics Patent for RLF-TD011 Biopharmaceuticals Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE published on 02/11/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics obtains European Patent Office grant for RLF-TD011, securing patent protection for epidermolysis bullosa treatment. Company advances wound care solution Relief Therapeutics European Patent Office Epidermolysis Bullosa Wound Treatment RLD-TD011
Published on 03/26/2026 at 23:00, 5 hours 40 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 6 hours 35 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 6 hours 40 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 6 hours 40 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 7 hours 40 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/27/2026 at 04:00, 39 minutes ago Tech-Driven Restoration: Saving the World's Critically Endangered White-headed Langur
Published on 03/26/2026 at 20:48, 7 hours 51 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 9 hours 19 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 9 hours 30 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 18:17, 10 hours 23 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 10 hours 23 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 10 hours 40 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 10 hours 40 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
